Munich, Germany (UroToday.com) In today’s castration resistant prostate cancer poster session at the 2016 EAU annual meeting, Dr. Keizman and colleagues presented their work on Radium-223 re-treatment from an international open label trial. Patients included in the study had completed 6 initial rounds of radium therapy with no evidence of skeletal progression, and as the primary outcome of interest was safety, patients on cytotoxic agents were excluded from the trial.
44 patients satisfied inclusion criteria and started retreatment at a median of 6 months from completion of primary therapy. Of these, 66% (n=29) completed the full course of re-treatment. All patients were on dual hormone agents, and 73% had failed abiraterone or enzalutamide.
Baseline age, ECOG status, and extent of disease were comparable to the ALSYMPCA trial. In the study, 3 patients had a grade 3 or 4 adverse event. 93% of patients had more than 1 TEAE, with anemia being the most common hematologic-related event (14%), and fatigue (27%), nausea (25%), and diarrhea (21%) being the most common non-heme events. Rate and severity of adverse events were on par with or lower than that of the ALSYMPCA trial. 1 patient demonstrated skeletal progression while 8 had soft tissue progression.
The investigators concluded that re-treatment with Radium-223 is safe, tolerable, and effective in delaying skeletal progression in men with mCRPC.
Presented By:
Keizman D.1, Nordquist L.T.2, Mariados N.3, Méndez Vidal M.J.4, Thellenberg Karlsson C.5, Peer A.6, Procopio G.7, Frank S.J.8, Pulkkanen K.9, Severi S.10, Trigo Perez J.M.11, Schwarzenberger P.12, Li R.13, Sartor O.14
Reported By:
Nikhil Waingankar, MD, at the 31st Annual EAU Congress - March 12 - 15, 2016 – Munich, Germany
Fox Chase Cancer Center